Planta Medica, Inhaltsverzeichnis Planta Med 2012; 78(3): 207-210DOI: 10.1055/s-0031-1298171 Rapid Communications© Georg Thieme Verlag KG Stuttgart · New YorkDiscovery of GABAA Receptor Modulator Aristolactone in a Commercial Sample of the Chinese Herbal Drug “Chaihu” (Bupleurum chinense Roots) Unravels Adulteration by Nephrotoxic Aristolochia manshuriensis RootsDiana C. Rueda1 , Janine Zaugg1 , Melanie Quitschau1 , Eike Reich2 , Steffen Hering3 , Matthias Hamburger1 1Division of Pharmaceutical Biology, University of Basel, Basel, Switzerland 2CAMAG Laboratory, Muttenz, Switzerland 3Institute of Pharmacology and Toxicology, University of Vienna, Vienna, Austria Artikel empfehlen Abstract Artikel einzeln kaufen Erratum zu diesem Artikel:Erratum for: Discovery of GABAA Receptor Modulator Aristolactone in a Commercial Sample of the Chinese Herbal Drug “Chaihu” (Bupleurum chinense Roots) Unravels Adulteration by Nephrotoxic Aristolochia manshuriensis RootsPlanta Med 2012; 78(03): E18-E18DOI: 10.1055/s-0031-1298366 Abstract In a two–microelectrode voltage clamp assay using Xenopus laevis oocytes, a petroleum ether extract prepared from a commercial sample of the traditional Chinese herbal drug labelled as “Chaihu” (Bupleurum chinense DC. roots) enhanced the I GABA by 156 % ± 22 % when tested at 100 µg/mL. By means of HPLC-based activity profiling combined with high-resolution LC-MS and microprobe NMR, the germacranolide aristolactone (1) was identified as one of the main active compounds (EC50 56.02 µM ± 5.09 µM). However, aristolactone has been previously reported only from the genus Aristolochia (Aristolochiaceae), suggesting a possible adulteration. With the aid of a validated HPTLC protocol for detection of aristolochic acids and with reference samples, the commercial sample was confirmed to be a mixture of Aristolochia manshuriensis root and Bupleurum chinense root. This finding was corroborated by macroscopic inspection of the drug. This case of adulteration with a highly nephrotoxic drug raises concerns about adequate quality control of TCM drugs commercialized in Europe. Key words Bupleurum chinense - Apiaceae - Aristolochia sp. - Aristolochiaceae - aristolactone - aristolochic acids - traditional Chinese medicine - adulteration Volltext Referenzen References 1 Zhao Z, Liang Z, Chan K, Lu G, Lee E L, Chen H, Li L. A unique issue in the standardization of Chinese materia medica: processing. Planta Med. 2010; 76 1975-1986 2 Zhao Z, Hu Y, Liang Z, Yuen J P, Jiang Z, Leung K S. Authentication is fundamental for standardization of Chinese medicines. Planta Med. 2006; 72 865-874 3 Chan K. Some aspects of toxic contaminants in herbal medicines. Chemosphere. 2003; 52 1361-1371 4 Zhao Z, Liang Z, Ping G. Macroscopic identification of Chinese medicinal materials: traditional experiences and modern understanding. J Ethnopharmacol. 2011; 134 556-564 5 Shaw D. Toxicological risks of Chinese herbs. Planta Med. 2010; 76 2012-2018 6 Jordan S A, Cunningham D G, Marles R J. Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicol Appl Pharmacol. 2010; 243 198-216 7 Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem J L. Identification of aristolochic acid in Chinese herbs. Lancet. 1994; 343 174 8 Vanherweghem J L, Tielemans C, Abramowicz D, Depierreux M, Vanhaelen-Fastre R, Vanhaelen M, Dratwa M, Richard C, Vandervelde D, Verbeelen D, Jadoul M. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet. 1993; 341 387-391 9 Yang X, Baburin I, Plitzko I, Hering S, Hamburger M. HPLC-based activity profiling for GABAA receptor modulators from the traditional Chinese herbal drug Kushen (Sophora flavescens root). Mol Div. 2011; 15 361-372 10 Zaugg J, Eickmeier E, Ebrahimi S N, Baburin I, Hering S, Hamburger M. Positive GABA(A) receptor modulators from Acorus calamus and structural analysis of (+)-dioxosarcoguaiacol by 1D and 2D NMR and molecular modeling. J Nat Prod. 2011; 74 1437-1443 11 Zaugg J, Baburin I, Strommer B, Kim H J, Hering S, Hamburger M. HPLC-based activity profiling: discovery of piperine as a positive GABA(A) receptor modulator targeting a benzodiazepine-independent binding site. J Nat Prod. 2010; 73 185-191 12 Potterat O, Hamburger M. Natural products in drug discovery – concepts and approaches for tracking bioactivity. Curr Org Chem. 2006; 10 899-920 13 Kim H J, Baburin I, Khom S, Hering S, Hamburger M. HPLC-based activity profiling approach for the discovery of GABAA receptor ligands using an automated two microelectrode voltage clamp assay on Xenopus oocytes. Planta Med. 2008; 74 521-526 14 Baburin I, Beyl S, Hering S. Automated fast perfusion of Xenopus oocytes for drug screening. Pflugers Arch. 2006; 453 117-123 15 Tian R T, Xie P S, Liu H P. Evaluation of traditional Chinese herbal medicine: Chaihu (Bupleuri Radix) by both high-performance liquid chromatographic and high-performance thin-layer chromatographic fingerprint and chemometric analysis. J Chromatogr A. 2009; 1216 2150-2155 16 Tang W, Eisenbrand G. Handbook of Chinese medicinal plants. Chemistry, pharmacology, toxicology. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2011 17 Huang K C. The pharmacology of Chinese herbs. Boca Raton: CRC Press LLC; 1999 18 Ashour M L, Wink M. Genus Bupleurum: a review of its phytochemistry, pharmacology and modes of action. J Pharm Pharmacol. 2011; 63 305-321 19 Chapman J. Chapman and Hall dictionary of natural products. Boca Raton: CRC Press, Hampden Ltd. Data Services; 2010 20 Blatter A, Reich E. High performance thin-layer chromatographic analysis of aristolochic acids in Chinese drugs. J Plan Chromatogr Modern TLC. 2004; 17 355-359 21 Cheung T P, Xue C, Leung K, Chan K, Li C G. Aristolochic acids detected in some raw Chinese medicinal herbs and manufactured herbal products – a consequence of inappropriate nomenclature and imprecise labelling?. Clin Toxicol (Phila). 2006; 44 371-378 22 Debelle F D, Vanherweghem J L, Nortier J L. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008; 74 158-169 23 Lai M N, Wang S M, Chen P C, Chen Y Y, Wang J D. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst. 2009; 102 179-186 24 Liang Y Z, Xie P S, Chan K. Perspective of chemical fingerprinting of Chinese herbs. Planta Med. 2010; 76 1997-2003 25 Sun S, Chen J, Zhou Q, Lu G, Chan K. Application of mid-infrared spectroscopy in the quality control of traditional Chinese medicines. Planta Med. 2010; 76 1987-1996 26 Heubl G. New aspects of DNA-based authentication of Chinese medicinal plants by molecular biological techniques. Planta Med. 2010; 76 1963-1974 27 Youns M, Hoheisel J D, Efferth T. Toxicogenomics for the prediction of toxicity related to herbs from traditional Chinese medicine. Planta Med. 2010; 76 2019-2025 28 Bauer R, Franz G. Modern European monographs for quality control of Chinese herbs. Planta Med. 2010; 76 2004-2011 29 Stöger E A. Arzneibuch der Chinesischen Medizin. Stuttgart: Deutscher Apotheker Verlag; 2001 30 European Directorate for the Quality of Medicines & Health Care .European Pharmacopoeia 7.0. Strasbourg: European Directorate for the Quality of Medicines & Health Care; 2011 Prof. Dr. Matthias Hamburger Division of Pharmaceutical BiologyUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland Telefon: +41 6 12 67 14 25 Fax: +41 6 12 67 14 74 eMail: Matthias.Hamburger@unibas.ch Zusatzmaterial Zusatzmaterial Supporting Information